Vimarsana
Biggest News Aggregation in the World

Page 14 - Foster Mitchell News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Foster Mitchell. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Foster Mitchell Today - Breaking & Trending Today

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Director Dealings - Vimarsana News

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Director Dealings

Investegate announcements from Diurnal Group PLC, Director Dealings

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: European Commission approval received for Efmody - Vimarsana News

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: European Commission approval received for Efmody

®         Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces the European Commission (EC) has approved the marketing authorisation for Efmody ® (hydrocortisone modified-release hard capsules - development name Chronocort ®) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). This decision by the EC follows the positive opinion issued by the European Medicines Agency (EMA) in March 2021. ...

Investegate |Novacyt S.A. Announcements | Novacyt S.A.: Launch of VersaLab Portable - Vimarsana News

Investegate |Novacyt S.A. Announcements | Novacyt S.A.: Launch of VersaLab Portable

Investegate announcements from Novacyt S.A., Launch of VersaLab Portable

Diurnal (AIM:DNL) | RNS | Diurnal Group PLC - Agreement with Citrine Medicine for Efmody - Vimarsana News

Diurnal (AIM:DNL) | RNS | Diurnal Group PLC - Agreement with Citrine Medicine for Efmody

$1.0 million and will receive $28.75 million in additional cash payments upon achievement of certain regulatory milestones and sales milestones based on annual sales thresholds. Diurnal will also receive tiered royalties on sales ranging from low to mid double-digits.   Citrine is a therapeutics platform company focused on the Greater China market that was co-founded by Vivo Capital, F-Prime Capital and Eight Roads Ventures. Citrine is focused on creating a therapeutic platform to deliver rare disease drugs to the Chinese market and to develop the first ever rare disease ecosystem in the c...

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Director Dealings - Vimarsana News

Investegate |Diurnal Group PLC Announcements | Diurnal Group PLC: Director Dealings

*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional bod...